GSA Capital Partners’s Collegium Pharmaceutical COLL Stock Holding History

GSA Capital Partners’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,757	Closed	-$359K	–	1791
2025 Q4	$359K	Sell	7,757 -14,528	-65%	-$608K	0.03%	1061
2025 Q3	$780K	Buy	+22,285	New	+$775K	0.07%	563
2019 Q4	–	Sell	-23,591	Closed	-$271K	–	1473
2019 Q3	$271K	Sell	23,591 -48,211	-67%	-$550K	0.04%	991
2019 Q2	$944K	Buy	71,802 +7,313	+11%	+$97.8K	0.11%	261
2019 Q1	$976K	Sell	64,489 -1,948	-3%	-$31.2K	0.1%	302
2018 Q4	$1.14M	Sell	66,437 -10,463	-14%	-$179K	0.13%	165
2018 Q3	$1.13M	Buy	76,900 +33,300	+76%	+$590K	0.06%	600
2018 Q2	$1.04M	Buy	+43,600	New	+$1.07M	0.05%	729

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

GSA Capital Partners's COLL Position: Q1 2026 in Review

GSA Capital Partners sold out of Collegium Pharmaceutical (COLL) in Q1 2026, closing a stake of 7,757 shares — an estimated $359K sold.

GSA Capital Partners first reported a position in COLL in Q2 2018 and held it in 8 quarters. The position peaked at $1.14M in Q4 2018. 267 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

GSA Capital Partners reported no remaining Collegium Pharmaceutical position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 7,757 Collegium Pharmaceutical shares in Q1 2026, an estimated $359K.
GSA Capital Partners first reported a position in Collegium Pharmaceutical in Q2 2018 and held it in 8 quarters.
GSA Capital Partners's Collegium Pharmaceutical position peaked at $1.14M in Q4 2018.
267 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.